Loading organizations...
Integrum AB has raised $5.5M across 2 funding rounds.
Key people at Integrum AB.
Integrum AB has raised $5.5M in total across 2 funding rounds.
Integrum AB develops and commercializes innovative systems for bone-anchored prostheses, primarily through its OPRA™ Implant System. This medical device solution leverages the osseointegration method, enabling direct attachment of a prosthesis to bone. The company's technology incorporates a unique BioHelix™ surface designed to promote rapid healing and stronger bone attachment, enhancing the stability and functionality of prostheses for users.
The company was founded in 1998 in Gothenburg, Sweden, by Dr. Rickard Brånemark and Dr. Per-Ingvar Brånemark. Dr. Per-Ingvar Brånemark, a pioneer in the field, coined the term "osseointegration" in 1962, performing the world's first surgery for a transfemoral osseointegrated prosthesis in 1990. Their foundational research and clinical experience directly informed Integrum's commercial development of bone-anchored prosthetics.
Integrum’s products serve individuals with amputations who seek alternatives to conventional socket prostheses, offering improved mobility and an enhanced quality of life. This includes partnerships with entities such as the US Department of Defense, recognizing the benefits for military patients. Integrum’s overarching vision is to provide freedom of mobility for every person, continually advancing its medical devices to support more active lifestyles.
Integrum AB has raised $5.5M across 2 funding rounds. Most recently, it raised $730K Integrum - Other Equity in November 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 10, 2025 | $730K Venture Round | Buntel | — | Announced |
| Jun 13, 2024 | $4.8M Series B | — | Adrigo Asset Management, Nolsterby Invest, Rhenman & Partners Asset Management | Announced |
Integrum AB has raised $5.5M in total across 2 funding rounds.
Integrum AB's investors include Buntel, Adrigo Asset Management, Nolsterby Invest, Rhenman & Partners Asset Management.
Key people at Integrum AB.
Integrum AB (publ) is a Swedish healthcare company specializing in bone-anchored prosthesis systems for amputees, primarily through its flagship OPRA Implant System based on osseointegration technology.[1][2][4][5] It serves hospitals, clinics, and orthopedists worldwide, solving the limitations of traditional socket prostheses by enabling direct skeletal attachment of artificial limbs, which improves mobility, reduces phantom limb pain via tools like Neuromotus, and supports a more active lifestyle.[1][2][4][5] The company, listed on Nasdaq Stockholm, focuses on medical equipment in the prosthetics sector, with sales concentrated in the USA, rest of the world, and Sweden, though specific growth figures show variability across fiscal years ending April.[1]
Founded in 1990 and headquartered in Mölndal, Sweden, Integrum emerged from pioneering research by Swedish professor Per-Ingvar Brånemark, who discovered osseointegration—the direct fusion of titanium implants with bone—during blood flow studies in rabbit bone.[2][4][5] The company's first surgery using this technique occurred in 1990, marking the start of continuous development for the OPRA system, which avoids socket-related issues like poor fit and skin irritation.[1][5] Early traction built on Brånemark's breakthrough, evolving into global sales of implant systems, neural prosthetics, and pain treatments, with patient stories highlighting restored daily activities and active lives post-amputation.[4][5]
Integrum rides the trend of advanced prosthetics and regenerative medicine, where osseointegration addresses rising amputation rates from trauma, diabetes, and cancer amid an aging global population.[1][5] Timing aligns with medtech advancements in biocompatible materials and implant durability, fueled by market forces like demand for non-invasive, patient-centric solutions over traditional prosthetics.[2][4] It influences the ecosystem by commercializing academic discoveries like Brånemark's, enabling active rehabilitation and setting standards for bone-anchored devices used in hospitals globally.[5]
Integrum's trajectory points to expanded OPRA adoption, potentially through regulatory approvals, partnerships, and R&D in neural interfaces amid growing medtech investments.[2][5] Trends like AI-enhanced prosthetics and personalized implants will shape its path, amplifying influence in rehabilitation as success metrics (e.g., 95.9% analyst upside) signal momentum.[2] This positions Integrum to transform amputee care, building on its 35-year legacy of turning osseointegration from miracle to everyday reality.[4][5]
